AstraZeneca ((AZN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: AstraZeneca is conducting a national multicenter non-interventional study titled ‘National Multicentre Non-interventional Study to Assess CRT Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia.’ The study aims to evaluate the patterns and short-term outcomes of chemo-radiation therapy (CRT) in patients with unresectable Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) across 50 oncology centers in Russia. This research is significant as it seeks to understand routine diagnostic and treatment approaches, potentially influencing future clinical practices.
Intervention/Treatment: The study focuses on observing the effects of CRT, a combination of chemotherapy and radiation therapy, on patients with unresectable locally advanced NSCLC and SCLC. The study does not involve any specific drug interventions but rather assesses existing treatment practices.
Study Design: This observational study follows a cohort model with a prospective time perspective. It involves secondary data collection from existing medical records of 2000 patients, capturing information at the start and after the completion of CRT, ensuring compliance with local regulatory requirements.
Study Timeline: The study began on April 21, 2023, and is currently recruiting participants. The primary completion and estimated study completion dates are not specified, but the last update was submitted on September 1, 2025. These dates are crucial for tracking the study’s progress and ensuring timely data collection and analysis.
Market Implications: This study update could positively impact AstraZeneca’s stock performance by demonstrating the company’s commitment to advancing cancer treatment. Investors may view this as a strategic move to strengthen AstraZeneca’s position in the oncology sector. The study’s findings could also influence treatment guidelines, potentially affecting competitors involved in similar research areas.
The study is ongoing, with further details available on the ClinicalTrials portal.